Clinical Trial

Tenofovir Alafenamide Switching Therapy in Kidney or Liver Transplant Recipients With Chronic HBV Infection

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
tenofovir alafenamide (TAF) has been approved to be highly effective and safe in patients with chronic hepatitis B (CHB), therefore TAF may be a good option in kidney or liver transplant patients with chronic HBV infection. The aim of this prospective cohort study is to assess the safety, efficacy, and drug adherence improvement of TAF switching therapy in kidney or liver transplant patients with HBV infection.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-06-06; most recent amendment 2026-04-28.
Status change: Recruiting → Active, Not Recruiting 2025-01-07
Trial Details
NCT Number NCT05410496
Lead Sponsor Taichung Veterans General Hospital
Collaborators: Institute of Adherence to Medication
Conditions Safety Issues, Chronic Hepatitis B, Transplant Recipient
Enrollment 52 participants
Start Date 2021-06-22
Primary Completion 2024-05-30 (estimated)
Study Completion 2027-07-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-04